3rd Quarter - Report

CAPITOL HILL CONSULTING GROUP for ENDO PHARMACEUTICALS

Firm
Client
Income
$40,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

Medical Device Tax Repeal; Stop Corporate Inversions Act (S.2360) (H.R.4679); issues relating to incentives for life sciences research; Protect Medical Innovation Act of 2013 (S.232) (H.R.523)

LobbyistCovered position, as disclosed
CHRISTOPHER BOWLIN New Committee 1999-2001
BILL K BREWSTER —
DAVID JORY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 232 (113th), H.R. 523 (113th), S. 2360 (113th), H.R. 4679 (113th)

Health Issues HCR

general health issues, including, but not limited to, coverage and reimbursement; drug importation; research and development; biosimiliars; Stop Tampering of Prescription Pills Act of 2013 (H.R. 486) Safeguarding America's Pharmaceuticals Act of 2013

LobbyistCovered position, as disclosed
CHRISTOPHER BOWLIN New Committee 1999-2001
BILL K BREWSTER —
DAVID JORY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 486 (113th)

Medicare/Medicaid MMM

general Medicare and Medicaid issues, including, but not limited to, coverage and reimbursement

LobbyistCovered position, as disclosed
CHRISTOPHER BOWLIN New Committee 1999-2001
BILL K BREWSTER —
DAVID JORY —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Pharmacy PHA

Ensuring Safe Access to Prescription Medication Act of 2014 (S.2825)

LobbyistCovered position, as disclosed
CHRISTOPHER BOWLIN New Committee 1999-2001
BILL K BREWSTER —
DAVID JORY —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 2825 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.